KLF4 and non-small cell lung carcinoma: A recent study has shown that glibenclamide, by targeting the K+ channel, modulates the expression of p70S6K and KLF4 in non-small cell lung cancer, and exerts an anticancer effect in both in vitro as well as in in vivo models [47].